

Press Release

ProStrakan Group plc

New PDUFA Action Date for Sancuso®

Galashiels, Scotland, 11 July, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received notification from the US Food and Drug Administration (FDA) that the action date for Sancuso®, ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been moved to Friday 18 July. ProStrakan understands that this delay is due to administrative, rather than technical, reasons.

As previously stated, ProStrakan remains confident of gaining US approval for Sancuso. Manufacturing of initial stocks is now under way in support of the planned US launch of this product in H2 2008, subject to completion of the US review process.

Ends

For more information on this announcement, please contact:

ProStrakan Corporate Dr Wilson Totten, Chief Executive Callum Spreng, Corporate Comms	+44 (0)1896 664000
Financial Dynamics David Yates / Ben Brewerton	+44 (0)20 7831 3113
Trout Group (for US investor enquiries) Gitanjali Jain	(646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. The company's development capability is centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries.
www.prostrakan.com